Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Medical Product Outsourcing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Medical Product Outsourcing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

FDA Guidance on Off-Label Communication, Part 2

55:41
 
Share
 

Manage episode 485792823 series 2805302
Content provided by Medical Product Outsourcing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Medical Product Outsourcing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re continuing our conversation on off-label communication. In this part, we’re examining the downside or negative aspects of this practice. We cover potential concerns and scenarios to avoid. Specifically, the following questions are addressed:

  • Mike, maybe you can kick things off with a very quick overview of what we previously covered in the first part of the conversation.
  • Now getting into that downside I mentioned in my opening, what are the disadvantages of off-label communication? In other words, what’s potentially wrong with allowing manufacturers to advertise uncleared or unapproved product claims?
  • Why are some (including some within the industry) opposed to giving manufacturers permission to advertise off-label claims?
  • Do you have any examples you can share?
  • Is it possible to find an appropriate balance between what claims should be vetted through the FDA and those that don’t need to be?
  • What happens when a company makes unsupported, deceptive, or completely false claims about a product?
  • In your professional opinion, should we allow a company to advertise unapproved claims that haven’t gone through a formal review process? Is it a good thing or a bad thing?
  • What else is important?
  • What are the most important takeaways?

Listen to this discussion after you’ve heard Part 1 and see what you think of off-label communication and the guidance. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at [email protected], and we’ll see if we want to address your ideas/inquiries/suggestions in a future episode.

Send us a text

For more medtech news and information, visit https://www.mpomag.com.

  continue reading

151 episodes

Artwork
iconShare
 
Manage episode 485792823 series 2805302
Content provided by Medical Product Outsourcing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Medical Product Outsourcing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re continuing our conversation on off-label communication. In this part, we’re examining the downside or negative aspects of this practice. We cover potential concerns and scenarios to avoid. Specifically, the following questions are addressed:

  • Mike, maybe you can kick things off with a very quick overview of what we previously covered in the first part of the conversation.
  • Now getting into that downside I mentioned in my opening, what are the disadvantages of off-label communication? In other words, what’s potentially wrong with allowing manufacturers to advertise uncleared or unapproved product claims?
  • Why are some (including some within the industry) opposed to giving manufacturers permission to advertise off-label claims?
  • Do you have any examples you can share?
  • Is it possible to find an appropriate balance between what claims should be vetted through the FDA and those that don’t need to be?
  • What happens when a company makes unsupported, deceptive, or completely false claims about a product?
  • In your professional opinion, should we allow a company to advertise unapproved claims that haven’t gone through a formal review process? Is it a good thing or a bad thing?
  • What else is important?
  • What are the most important takeaways?

Listen to this discussion after you’ve heard Part 1 and see what you think of off-label communication and the guidance. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at [email protected], and we’ll see if we want to address your ideas/inquiries/suggestions in a future episode.

Send us a text

For more medtech news and information, visit https://www.mpomag.com.

  continue reading

151 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play